As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: August 28, 2012
by Doctors Lounge:
Levels of five different cerebrospinal fluid (CSF) biomarkers are able to improve differentiation between common dementia and parkinsonian disorders, according to a study published online Aug. 27 in the Archives of Neurology.
Sara Hall, M.D., from Lund University in Sweden, and colleagues assessed the ability of five CSF biomarkers to differentiate between 453 CSF samples from healthy controls and patients with Parkinson’s disease (PD), PD with dementia (PDD), dementia with Lewy bodies (DLB), Alzheimer’s disease (AD), progressive supranuclear palsy (PSP), multiple system atrophy (MSA), or corticobasal degeneration (CBD).
The researchers found that CSF levels of α-synuclein were increased in patients with AD and decreased in patients with PD, PDD, DLB, and MSA. Decreased levels of β-amyloid 1-42 were seen in DLB. In AD, β-amyloid 1-42 levels were further decreased and CSF levels of total tau and hyperphosphorylated tau were increased.
These biomarkers were able to distinguish AD from DLB and PDD with an area under the curve of 0.90, with the main contribution from α-synuclein and total tau. In atypical parkinsonian disorders (PSP, MSA, and CBD), CSF levels of neurofilament light chain were increased, and that level alone could be used to differentiate PD from atypical parkinsonian disorders with an area under the curve of 0.93.
“Together with earlier published data, our results indicate that these five CSF biomarkers might have clinical value in the differential diagnosis of dementia and/or parkinsonism,” Hall and colleagues conclude.
Thirty-six million people worldwide suffer from Alzheimer’s disease and dementia. In Canada, 25,000 new cases are diagnosed each year. Those sobering numbers have researchers around the globe racing to come up with new ways to...
he Food and Drug Administration issued new guides on drug development for neurological disorders. This sets the stage for possible treatments for Alzheimer’s. The disease-oriented development guide documents will provide details on how researchers...
For young adults with autosomal dominant Alzheimer’s disease (AD), molecular markers can identify changes associated with the disease before clinical onset, according to a study published online Feb. 12 in JAMA Neurology. Yakeel T. Quiroz, Ph.D., from Massachusetts...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.